GlaxoSmithKline split its corporate structure into distinct entities, separating its consumer healthcare division into a newly independent company named Haleon plc, while its core biopharma and prescription medicines enterprise retained the established GlaxoSmithKline (GSK) corporate name. This strategic separation allowed both entities to independently focus on consumer wellness products and specialized vaccine development respectively.